15573-98-5

Basic information

• Product Name: (1,3-dioxohexahydro-4,7-epoxy-2-benzofuran-4(1H)-yl)methyl acetate
• CAS NO: 15573-98-5
• Molecular Formula: C₁₁H₁₂O₆
• Molecular Weight: 240.2094
• Mol File: 15573-98-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 409.8°C at 760 mmHg
• Flash Point: 186.1°C
• Density: 1.439g/cm³
• Vapor Pressure: 6.31E-07mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: (1,3-dioxohexahydro-4,7-epoxy-2-benzofuran-4(1H)-yl)methyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (1,3-dioxohexahydro-4,7-epoxy-2-benzofuran-4(1H)-yl)methyl acetate(15573-98-5)
• EPA Substance Registry System: (1,3-dioxohexahydro-4,7-epoxy-2-benzofuran-4(1H)-yl)methyl acetate(15573-98-5)

Safety Data

• Hazardous Substances Data: 15573-98-5(Hazardous Substances Data)

Usage

General Description

(1,3-dioxohexahydro-4,7-epoxy-2-benzofuran-4(1H)-yl)methyl acetate is a chemical compound with a complex structure and diverse potential applications. It is a derivative of benzofuran, a heterocyclic compound commonly used in the pharmaceutical and agrochemical industries. This specific chemical may have potential applications in pharmaceuticals, as benzofuran derivatives have been explored for their anti-cancer, anti-inflammatory, and antiviral properties. The acetate group in the compound also indicates a potential use as a solvent or intermediate in organic synthesis. However, further research and investigation into the properties and potential uses of this compound are likely needed to fully understand its significance.

Upstream product

• 623-17-6 furfurylacetate 
• 98-00-0 (2-furyl)methyl alcohol 
• 6331-95-9 (+/-)-(1RS,2SR,6RS,7SR)-(3,5-dioxo-4,10-dioxatricyclo[5.2.1.0^2,6]dec-8-en-1-yl)methyl acetate 

Relevant articles and documents

Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin)

Protein serine/threonine phosphatases (PP1, PP2A and PP2B) play important roles in intracellular signal transductions. The immunosuppressant drugs FK506 and cyclosporin A (CsA) bind to immunophilins, and these complexes selectively inhibit PP2B (calcineurin), leading to the suppression of T-cell proliferation. Both FK506 and CsA must, however, form complexes with immunophilins to exert their inhibitory action on PP2B. Thus, it is of interest to find a direct and selective inhibitor of PP2B that does not involve the immunophilins as a biological tool for studies of PP2B and also as a candidate therapeutic agent. We selected the simple natural product cantharidin, a known PP2A-selective inhibitor, as a lead compound for this project. Primary SAR indicated that norcantharidin (7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride) inhibits not only PP1 and PP2A but also PP2B, and a binding model of norcantharidin carboxylate to the PP2B catalytic site was computationally constructed. Based on this binding model, we designed and synthesized several cantharidin derivatives. Among these compounds, 1,5-dibenzoyloxymethyl-substituted norcantharidin was found to inhibit PP2B without inhibiting PP1 or PP2A. To our knowledge, this is the first highly selective catalytic site-directed inhibitor of PP2B.